Transdermal selegiline for the treatment of major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 5, 2007, Pages 527-537

  Lee, Kelly C ^a,c   Chen, Jack J ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

EMSAM ; Major depressive disorder; Monoamine oxidase inhibitor; Selegiline; Transdermal

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; BUSPIRONE; CARBAMAZEPINE; CYCLOBENZAPRINE; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; EPHEDRINE; ISOCARBOXAZID; ISOENZYME; LINEZOLID; METHADONE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; OXCARBAZEPINE; PETHIDINE; PHENELZINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PLACEBO; PSEUDOEPHEDRINE; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

APPLICATION SITE REACTION; ARTICLE; CHEESE; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INHIBITION; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PHARYNGITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUSITIS; WEIGHT GAIN; XEROSTOMIA;

EID: 36048935973     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Clinical Trials.gov. 2007. [online]. National Library of Medicine. Accessed June 26, 2007. URL: www.clinicaltrials.gov.
2. Amsterdam JD. 2003. A double-blind, placebo-controlled trial ofthe safety and efficacy of selegiline fiansdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry, 64:208-14.
3. Amsterdam JD, Bodkin JA. 2006. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol, 26:579-86.
4. [APA] American Psychiatric Association. 2000. Practice guideline for the treatment of patients with major depressive disorder (revision). APA. Am J Psychiatry, 157(Suppl):1-45.
5. Azzaro AJ, Vandenberg CM, Blob LF, et al. 2006. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/ 24 h in healthy subjects. J Clin Pharmacol, 46:933-44.
6. Azzaro AJ, Vandenberg CM, Ziemniak J, et al. 2007a. Evaluation of the potential for pharmacodynamic and pharmacokinetic chug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. J Clin Pharmacol, 47:978-90.
7. Azzaro AJ, Ziemniak J, Kemper E, et al. 2007b. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol, 47:146-58.
8. Barrett JS, Hochadel TJ, Morales RJ, et al. 1996. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther, 3:688-98.
9. Bieck PR, Antonin KH. 1988. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol, 8:237-45.
10. Blackwell B. 1963. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet, 38:849-50.
11. Blackwell B, Mabbitt LA. 1965. Tyramine in cheese related to hypertensive crises after monoamine-oxidase inhibition. Lancet, 62:938-40.
12. Blackwell B, Marley E, Price J, et al. 1967. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychialry, 113:349-65.
13. Blob LF Sharosky M, Campbell BJ, et al. 2007. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr, 12:25-34.
14. Bodkin JA, Amsterdam JD. 2002. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry, 159:1869-75.
15. Bridge JA, Iyengar S, Salary CB, et al. 2007. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA, 297:1683-96.
16. Clary C, Mandos LA, Schweizer E. 1990. Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. J Clin Psychiatry, 51:226-31.
17. Cooper AJ. 1989. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry, (Suppl 6):3 8-45.
18. Da Prada M, Zurcher G, Wuthrich I, et al. 1988. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm, Suppl, 26:31-56.
19. Evans RW, Bigal ME, Grosberg B, et al. 2006. Target doses and titration schedules for migraine preventive medications. Headache, 46:160-4.
20. Feiger AD, Rickels K, Rynn MA, et al. 2006. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry, 67:1354-61.
21. Feinberg SS. 2004. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry, 65:1520-4.
22. Georgotas A, McCue RE, Hapworth W, et al. 1986. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry, 21:1155-66.
23. Goldberg LL 1964. Monoamine oxidase inhibitors. adverse reactions and possible mechanisms. JAMA, 190:456-62.
24. Gordon MN, Muller CO, Sherman KA, et al. 1999. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav, 63:501-6.
25. Hidestrand M, Oscarson M, Salonen JS, et al. 2001. CYP2136 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos, 29:1480-4.
26. Hoffinan BB, Lefkowitz RJ. 1996. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In Hardman JG, Limbird LE, Molinoff PB, et al. eds. Goodman and Gilman's The Pharmacological basis of therapeutics. New York: McGraw-Hill. p 199-248.
27. Houtsmuller EJ, Notes LD, Newton T, et al. 2004. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl), 172:31-40.
28. Kamada T, Chow T, Hiroi T, et al. 2002. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet, 17:199-206.
29. Kessler RC, Berglund P, Demler O, et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-105.
30. Liebowitz MR, Hollander E, Schneier F, et al. 1990. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand, (Suppl) 360:29-34.
31. Liebowitz MR, Schneier F, Campeas R, et al. 1992. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry, 49:290-300.
32. Lin EH, Von Korff M, Ludman EJ, et al. 2003. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry, 25:303-10.
33. Mahmood I. 1997. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet, 33:91-102.
34. Mann JJ, Aarons SF, Wilner PJ, et al. 1999. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry, 46:45-50.
35. Mawhinney M, Cole D, Azzaro AJ. 2003. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol, 55:27-34.
36. McDaniel KD. 1986. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol, 9:207-34.
37. McGrath PJ, Stewart JW, Fava M, et al. 2006. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry, 163:1531-41; quiz 1666.
38. McGrath PJ, Stewart JW, Harrison W, et al. 1987. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull, 23:169-72.
39. Olfson M, Marcus SC, Tedeschi M, et al. 2006. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry, 163:101-8.
40. Quitkin FM, Stewart JW, McGrath PJ, et al. 1988. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry, 145:306-11.
41. Rabkin J, Quitkin F, Harrison W, et al. 1984. Adverse reactions to monoamine oxidase inhibitors. Part 1. A comparative study. J Clin Psychopharmacol, 4:270-8.
42. Reimann IW, Firkusny L, Antonin KH, et al. 1992. Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences. Eur J Clin Pharmacol, 42:137-41.
43. Roose SP, Glassman AH, Walsh BT, et al. 1986. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry, 143:345-8.
44. Sacktor N, Schifitto G, McDermott MP, et al. 20M. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology, 54:233-5.
45. Salonen JS, Nyman L, Boobis AR, et al. 2003. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos, 31:1093-102.
46. Saura Marti J, Kettler R, Da Prada M, et al. 1990. Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm, (Suppl) 32:49-53.
47. Schulz R, Antonin KH, Hoffmann E, et al. 1989. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther, 46:528-36.
48. Shin HS. 1997. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos, 25:657-62.
49. Shulman KI, Walker SE. 1999. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry, 60:191-3.
50. Shulman KI, Walker SE, MacKenzie S, et al. 1989. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol, 9:397-402.
51. Simon GE. 2006. The antidepressant quandary - considering suicide risk when treating adolescent depression. N Engl J Med, 355:2722-3.
52. Somerset Pharmaceuticals I. 2006. EMSAM(r) Selegiline Transdermal System, Princeton.
53. Sunderland T, Cohen RM, Molchan S, et al. 1994. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry, 51:607-15.
54. Taavitsainen P, Anttila M, Nyman L, et al. 2000. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol, 86:215-21.
55. Taylor JJ, Wilson JW, Estes LL. 2006. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis, 43:180-7.
56. Walker SE, Shulman KI, Tailor SA, Gardner D. 1996. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol, 16:383-8.
57. Youdim. MBH, Finberg JPM. 1983. Monoamine oxidase. In: Lajtha A. ed. Handbook of neurochemistry. Enzymes in the nervous system. New York: Plenum Press. p 293-313.